
**Dear Editor,**

Hyperornithinaemia-hyperammonaemia-homocitrullinuria (HHH) syndrome (OMIM #238970) is a rare autosomal recessive disorder associated with mutations of the SLC25A15 gene which encodes the mitochondrial ornithine transporter 1 (ORNT1).\(^1\) ORNT1 is responsible for the transport of cytosolic ornithine into the mitochondria in exchange for citrulline in the urea cycle and ornithine degradation pathway. A defect in this transporter results in accumulation of ornithine in the cytosol (resulting in hyperornithinaemia), disruption of the urea cycle (resulting in hyperammonaemia) and increased secretion of homocitrulline in urine (a product of transcarbamoylation of lysine). This biochemical reaction cascade is affected by protein load in the diet.\(^2\)

It is challenging to diagnose HHH syndrome as it is not detected on newborn metabolic screening.\(^3\) Hyperornithinaemia develops beyond infancy and hyperammonaemia tends to be milder compared to other urea cycle disorders. However, it is a preventable cause of intellectual disability, and prompt diagnosis with appropriate management can improve long-term outcome and quality of life for patients. HHH syndrome was first described in 1969 by Shih and colleagues\(^4\) and it constitutes only 1% to 3% of all urea cycle disorders.\(^5\) HHH syndrome has the highest prevalence among French-Canadians, followed by Italians and Japanese.\(^6\) HHH syndrome has not been reported locally and only been reported once previously in an individual of Indian descent.\(^7\) We describe an additional case of a girl of Indian descent, who presented with recurrent episodes of altered mental state in association with febrile illnesses and was subsequently diagnosed with HHH syndrome.

**Clinical Report**

An 11-year-old Indian girl presented to our hospital with altered mental state in association with acute upper respiratory tract illness. She was feeding less due to poor appetite and had vomiting prior to admission. She had no fever. She took oral dexamethasone, clarithromycin and dextromethorphan for 2 days before admission. She was found to be confused and unable to recognise her family or surroundings. Physical examination revealed a well-thrived child. She had spontaneous eye opening and was able to move her limbs voluntarily. However, she was disoriented to time, place and person. She was afebrile. She was mildly tachypnoeic but the respiratory examination did not reveal any abnormality. Neurological evaluation revealed symmetrical hyperreflexia over bilateral knee and ankle joints with bilateral abnormal Babinski sign. She did not have ankle clonus and her strength was full. Her sensory examination was normal and she did not exhibit neck stiffness or any signs of cerebellar involvement (nystagmus, dysmetria, dysdiakinesia, ataxia or pendular reflexes). She had no hepatosplenomegaly.

She is the second child of non-consanguineous parents of Indian descent. She had a maternal uncle who passed away in infancy of unknown cause. She had a personal preference for a protein restricted vegetarian diet because she felt unwell after consuming meat. Besides asthma, she had a previous admission at 5 years of age where she had experienced a brief period of altered mental state. It occurred during an episode of acute asthma exacerbation and had resolved spontaneously. She did not require intravenous hydration during that admission. No further workup was done at that point of time in view of the spontaneous remission of symptoms. She was developmentally appropriate and was coping in mainstream school, albeit with poor performance in Mathematics.

Brain magnetic resonance imaging (MRI), electroencephalogram and cerebrospinal fluid (CSF) biochemical analysis were normal. Blood investigations were significant for mild respiratory alkalosis (pH 7.466, pCO\(_2\) 34.4 mmHg, pO\(_2\) 68 mmHg, BE 1, HCO\(_3\) 24.8 mmol/L) and mildly elevated alanine transaminase at 44 U/L, (normal range 9 to 25 U/L). Her coagulation profile was normal. Ammonia levels revealed mild hyperammonaemia (84 µmol/L, reference range 9 to 33 µmol/L). In view of her encephalopathy, hyperammonaemia, respiratory alkalosis and a history of protein aversion, a possible diagnosis of a urea cycle disorder was suspected. Plasma amino acid analysis showed elevations of glutamine (881 µmol/L; normal range 400 to 750 µmol/L) and ornithine (197 µmol/L; normal range 35 to 155 µmol/L) with citrulline and arginine levels within their respective normal reference ranges. No arginosuccinic acid was detected. Orotic acid was present and abnormally raised in the urine [orotic acid to creatinine

---

**Annals Academy of Medicine**

---

**SLC25A15**

**ORNT1**

**HHH syndrome**

**Sensory examination**

**Neurological evaluation**

**Hyperammonaemia**

**Hyperornithinaemia**

**Brain magnetic resonance imaging (MRI)**

**Electroencephalogram**

**Cerebrospinal fluid (CSF)**

**Respiratory alkalosis**

**Ammonia levels**

**Plasma amino acid analysis**

**Orotic acid**

---

**Note:** The above text is a clinical report of a teenage girl presenting with recurrent episodes of altered mental state associated with hyperammonaemia and hyperornithinaemia, likely due to a rare urea cycle disorder known as HHH syndrome. The report highlights the clinical features, diagnostic approach, and management of such cases, emphasizing the importance of prompt diagnosis and appropriate management to improve long-term outcomes.
Table 1. Comparison of the Clinical Presentation of Previously Reported Cases of HHH with Our Patient

<table>
<thead>
<tr>
<th>Ethnic group</th>
<th>Debray et al*</th>
<th>Miyamoto et al†</th>
<th>Tunali et al‡</th>
<th>Tezcan et al§</th>
<th>Lee et alǁ</th>
<th>Our Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>16</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Age of presentation (years)</td>
<td>2.7#</td>
<td>52†† and 10‡‡</td>
<td>6</td>
<td>35</td>
<td>&lt;1 (1 month)</td>
<td>11</td>
</tr>
<tr>
<td>Initial clinical presentation</td>
<td>Neurological symptoms</td>
<td>9/16</td>
<td>2/2</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Enecephalopathy</td>
<td>3/16</td>
<td>2/2</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Liver dysfunction</td>
<td>6/16</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Yes</td>
<td>Mildly elevated transaminases</td>
</tr>
<tr>
<td>Hyperammonaemia</td>
<td>12/16</td>
<td>2/2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Ammonia level at presentation (µmol/L)</td>
<td>146</td>
<td>90* and 132‡‡</td>
<td>300</td>
<td>114</td>
<td>132</td>
<td>84</td>
</tr>
</tbody>
</table>

¶Patient 2 in the study was excluded as he was diagnosed by screening due to family history.
#Median.
**All are homozygous p.F188del except 1 patient with p.F188del with a second unidentified mutation.
*Patient 1.
††Patient 2.

Urine amino acid analysis showed a small but distinguishable peak corresponding to the retention time of homocitrulline. This finding in combination with hyperornithinaemia and hyperammonaemia suggested a possible diagnosis of HHH syndrome. Due to the presence of mild ornithine aciduria in the biochemical workup, as well as family history of male neonatal death, the differential diagnosis considered for our patient was that of a heterozygous female presenting with partial ornithine transcarbamylase (OTC) deficiency, a more well known metabolic cause of recurrent encephalopathy in females. Sanger sequencing of OTC gene was negative. Sanger sequencing of SLC25A15 gene revealed that she was compound heterozygous for 2 variants (c.88T>G; p.F30V and c.113A>C; p.Q38P). One of the variants c.113A>C; p.Q38P is known to be a pathogenic mutation, while the second is a novel variant c.88T>G; p.F30V. This variant was absent from dbSNP141, 1000 Genomes, Exome Aggregation Consortium and Exome Variant Server. The novel variant alters a highly conserved amino acid residue and was predicted by in silico prediction algorithms to be pathogenic. Parents were offered genetic testing of SLC25A15 gene to phase the variants, as well as to determine their carrier status, but they declined due to financial constraints.

She was given intravenous dextrose drip after admission with improvements in her ammonia level to 44 µmol/L. After she was diagnosed with HHH syndrome, she was continued on a protein restricted diet (0.9 g protein/kg/day) and started on oral sodium benzoate which led to normal ammonia...
levels as well as initial improvement in her cognition and academic performance. She was educated on emergency feeding regimen including being on protein-free diet and high caloric carbohydrate drinks during sick days. She is now 12 years old and occasionally misses her medications and medical appointments. We continue to engage her and her family to improve compliance.

Discussion

This is the first case reported in the local population and the second case reported in an individual of Indian ethnicity, the former being a 35-year-old college graduate male from India with a history of protein restriction in his diet who had no neurological or neurocognitive deficits prior to presentation.\(^7\) Both individuals had a history of self-restriction of protein in the diet and thus were generally asymptomatic. This likely contributed to the late clinical presentation and diagnosis. They both had episodic decompensation causing neurological symptoms and their conditions are stable with diet control and medications. Our patient had homocitrullinuria, while this was absent in the previously published case.

Compared to the reported clinical features of patients with HHH syndrome,\(^6\) she shared some of the commonest clinical features of pyramidal signs, lethargy and abnormal behaviour. Most patients, like ours, were diagnosed between 1 to 12 years of age. In Table 1, we compared our patient with those reported previously in literature and include individuals of French-Canadian,\(^8\) Japanese,\(^9\) Chinese\(^10\) and Turkish\(^2\) descent. Although, there is a common founder mutation in the French-Canadian patients (p.F188del), there are no obvious differences in the phenotype among patients of different ethnic groups. In addition, there is a lack of phenotype-genotype correlation among patients with HHH syndrome, where individuals with the same genetic mutation may have different age of presentation and varying clinical outcomes.\(^2\) Affected individuals have unremarkable antenatal and birth histories and varied clinical presentations ranging from prolonged hyperbilirubinaemia,\(^10\) mild neurocognitive deficits to seizures, gait disturbances, stroke-like episodes and life threatening presentations of encephalopathy and liver failure.\(^11\) The diagnosis can be easily missed because the encephalopathy and mild hyperammonaemia can be treated merely by intravenous dextrose drip which is typically given for patients with vomiting and poor feeding.

Conclusion

In conclusion, we report the first local case of HHH syndrome. Although our patient is only the second case of Indian origin, she shared many clinical features with previously reported patients from other ethnic groups. HHH syndrome should be considered in any female with mild hyperammonaemia, raised urine orotic acid and negative gene analysis for OTC gene. Early diagnosis and appropriate management can prevent life threatening complications and improve overall quality of life.

Acknowledgement

The authors would like to thank the patient and her family reported herein for their participation in this research. SSJ is supported by the Nurturing Clinician Scientist Scheme, SingHealth Duke-NUS Academic Clinical Programme.

REFERENCES


Address for Correspondence: Dr Saumya Shekhar Jamuar, Department of Paediatrics, KK Women’s and Children’s Hospital, 100 Bukit Timah Road, Singapore 229899.

Email: Saumya.s.jamuar@kkh.com.sg